New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials

NCT ID NCT06380660

Ongoing Disease control Sponsor: Acerand Therapeutics (Shanghai) Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or stopping tumor growth. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors in people with cancers like ovarian, breast, or prostate cancer linked to BRCA gene mutations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition breast cancer breast neoplasm neoplasm ovarian cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 MUTATION BRCA2 MUTATION BREAST CANCER OVARIAN CANCER PROSTATE CANCER SOLID TUMOR, ADULT

Contacts and locations

Locations

Anyang Cancer Hospital

Anyang, Henan, China
Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, China
First Hospital Affiliated to Wenzhou Medical University

Wenzhou, Zhejiang, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China
Fujian Cancer Hospital

Fuzhou, Fujian, China
Henan Cancer Hospital

Zhengzhou, Henan, China
Hubei Cancer Hospital

Wuhan, Hubei, China
Hunan Cancer Hospital

Changsha, Hunan, China
Jinan Central Hospital

Jinan, Shandong, China
Qilu Hospital Shangdong University

Jinan, Shandong, China
Second Hospital Affiliated to Shanxi Medical University

Taiyuan, Shanxi, China
Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.